Land: Australia
Språk: engelsk
Kilde: Department of Health (Therapeutic Goods Administration)
Emtricitabine; Efavirenz; Tenofovir disoproxil fumarate
Gilead Sciences Pty Ltd
Medicine Registered
Page 1 ATRIPLA CMI v2.1 – (19January2010) CONSUMER MEDICINE INFORMATION ATRIPLA ® TABLETS (300 MG TENOFOVIR DISOPROXIL FUMARATE / 200 MG EMTRICITABINE/ 600 MG EFAVIRENZ) WHAT IS IN THIS LEAFLET READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. This leaflet answers some of the common questions about ATRIPLA tablets. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist about your medical condition or treatment. If you have further questions, please ask your doctor or your pharmacist. Keep this leaflet with your ATRIPLA medicine. You may need to read it again. This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours. WHAT IS ATRIPLA? • ATRIPLA consists of three medicines VIREAD ® (tenofovir disoproxil fumarate, also called tenofovir DF), EMTRIVA ® (emtricitabine or FTC) and STOCRIN ® (efavirenz) combined in one tablet. • VIREAD and EMTRIVA belong to a group of antiviral medicines known as nucleoside and nucleotide reverse transcriptase inhibitors (NRTI) and STOCRIN belongs to a group of antiviral medicines known as non-nucleoside reverse transcriptase inhibitors (NNRTI). Tenofovir DF and emtricitabine are the components of TRUVADA ® tablets. • ATRIPLA is used to treat Human Immunodeficiency Virus (HIV) infection in adults. This medicine can be taken alone or in combination with other anti-HIV medicines. • HIV infection destroys CD4 + T cells, which are important to the immune system. The immune system helps fight infection. After a large number of T cells are destroyed, acquired immune de read_full_document
ATRIPLA Product Information v8.0 – (3 September2013) Page 1 of 32 PRODUCT INFORMATION ATRIPLA ® (TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE AND EFAVIRENZ) TABLETS NAME OF THE MEDICINE ATRIPLA (300 mg tenofovir disoproxil fumarate/200 mg emtricitabine/600 mg efavirenz) tablets. The active substances in ATRIPLA tablets are tenofovir disoproxil fumarate (tenofovir DF), emtricitabine and efavirenz. VIREAD ® is the brand name for tenofovir DF, which is converted _in vivo_ to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate. EMTRIVA ® is the brand name for emtricitabine (FTC), a synthetic nucleoside analog of cytidine. STOCRIN _®_ is the brand name for efavirenz, a non-nucleoside reverse transcriptase inhibitor. All three compounds exhibit activity against HIV-1 reverse transcriptase. Tenofovir DF and emtricitabine are the components of TRUVADA ® . DESCRIPTION _TENOFOVIR DISOPROXIL FUMARATE_: Tenofovir DF is a fumaric acid salt of the _bis_- isopropoxycarbonyloxymethyl ester derivative of tenofovir. The chemical name of tenofovir DF is 9-[(_R_)-2 [[bis[[(isopropoxycarbonyl)oxy] methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C 19 H 30 N 5 O 10 P C 4 H 4 O 4 and a molecular weight of 635.52. It has the following structural formula: N N N N O P O O O O O O NH 2 CH 3 CO 2 H H HO 2 C H O O O CAS registry number: 202138-50-9 Tenofovir DF is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25 C. The partition coefficient (_log p_) for tenofovir disoproxil is 1.25 and the pKa is 3.75. _ read_full_document